Postural orthostatic tachycardia syndrome (POTS) is a variant of cardiovascular autonomic disorder characterized by an excessive heart rate increase on standing and orthostatic intolerance. POTS affects younger individuals 15-45 years old with a distinct female predominance (%80%). The prevalence ranges between 0.2% and 1.0% in developed countries. The onset of POTS is typically precipitated by immunological stressors such as viral infection, vaccination, trauma, pregnancy, surgery or psychosocial stress. The most common complaints are dizziness, weakness, rapid heartbeat and palpitation on standing. Moreover, patients often report physical deconditioning and reduced exercise capacity as well as headache, 'brain fog', dyspnoea, gastrointestinal disorders and musculoskeletal pain. The aetiology of POTS is largely unknown and three main hypotheses include an autoimmune disorder, abnormally increased sympathetic activity and catecholamine excess, and sympathetic denervation leading to central hypovolaemia and reflex tachycardia. The golden standard for POTS diagnosis is head-up tilt test with a non-invasive beat-to-beat haemodynamic monitoring. Although long-term prognosis of POTS is poorly explored, around 50% of patients spontaneously recover within 1-3 years. After the diagnosis has been established, patient should be thoroughly educated about non-pharmacological measures alleviating the symptoms. Exercise training may be very effective and counteract deconditioning. In more symptomatic patients, different drugs directed at controlling heart rate, increasing peripheral vasoconstriction and intravascular volume can be tested. However, the overall effects of pharmacological therapy are modest and the most affected patients remain handicapped. Future efforts should focus on better understanding of POTS pathophysiology and designing randomized controlled trials for selection of more effective therapy.
Introduction
Postural orthostatic tachycardia syndrome (POTS) is a common, although not so well-known variant of cardiovascular autonomic disorder characterized by an excessive heart rate increase on standing, symptoms of orthostatic intolerance and occasional syncope [1] [2] [3] [4] . The syndrome affects younger individuals, with a distinct predominance of women (%80%) [3, 5] . The prevalence estimates are imprecise and range between 0.2% and 1.0% in US population totalling in approximately 0.5 million patients [3, 5, 6] , while European data are largely not available. The term 'POTS' was first used in 1993 by Schondorf and Low from Mayo Clinic for description of sudden-onset idiopathic pandysautonomia with prevailing hyperadrenergic circulatory symptoms and abnormal orthostatic heart rate acceleration [7] . However, reports about similar conditions can be found earlier in the medical literature. In 1871, Da Costa published his observations on abnormal postural tachycardia, typically following intestinal infection, combat wounds or excessive effort among young soldiers during the American Civil War, an abnormality he called 'an irritable heart' [8] . In 1920s, a similar report came from Sweden, where 'arterial orthostatic anaemia' characterized by pronounced heart rate increase on standing and deconditioning among young women were described by Bjure and Laurell [9] . In the following years, sporadic case reports appeared in the literature, portraying young individuals, often women, with characteristic postural tachycardia and reduced physical exercise capacity [10] [11] [12] [13] [14] [15] [16] ; however, long-term prognosis was not elucidated.
In the wake of their report from 1993, the Mayo Clinic group proposed diagnostic criteria of POTS, which were heart rate increase >30 beats min À1 or above 120 beats min À1 within first 5 min after assuming standing position, accompanied by symptoms of orthostatic intolerance [17] . These criteria were subsequently endorsed by major international neurologic, autonomic and cardiologic societies with slight modifications [1, 3, 4] (Table 1 -criteria).
In the past two decades, the number of publications on POTS has been steadily increasing; however, it is unclear whether this is due to the fact that the syndrome has been recognized as a unique clinical entity or that we are rather witnessing a new epidemic emerging in the developed countries [18, 19] . The reasons for growing interest in POTS are its enormous impact on patients' quality of life as well as unresolved diagnostic and therapeutic difficulties. In this review, we will discuss characteristic clinical presentation, presumptive aetiology, epidemiology and current management of the syndrome.
Review methodology
The author performed a PubMed literature search for publications prior to 1993 using 'orthostatic tachycardia' and 'postural tachycardia' as keywords. Then, the author scanned selected publications and their reference lists for other relevant publications, which were not identified by the preliminary search. In the next stage, the term 'postural (orthostatic) tachycardia syndrome' was used to identify all pertinent publications from January 1993 to August 2018. In addition, the author completed the literature search with scientific reports and publications from his own collection, if not found in previous stages. The selection This criterion may be controversial and is not unanimously accepted as patients may seek medical advice earlier due to increasing awareness of the syndrome. However, symptoms of shorter duration than 3 months should be re-evaluated to confirm the diagnosis.
of the most relevant papers according to author's opinion was included in this review.
The definition and clinical presentation of POTS

Diagnostic criteria of POTS
The current diagnostic criteria for POTS are summarized in Table 1 . The criteria are consistent in major parts across various consensus documents, although many authors emphasize the fact that overlap between POTS and other disorders, in particular orthostatic hypotension, vasovagal syncope, panic disorders, psychogenic pseudosyncope, chronic fatigue syndrome, Ehlers-Danlos syndrome and cardiac arrhythmias may exist and should be considered in complex cases [3] [4] [5] 20] .
Clinical presentation of POTS
A characteristic patient with POTS is a young woman about 25 years old, reporting first symptoms at age around 15 years, although the range of disease onset may extend until fifth decade of life and one-fifth are men [21, 22] . In a specialized syncope unit, almost one-third of patients aged 18-40 years with a history of unexplained syncope and pronounced orthostatic intolerance may meet the diagnostic POTS criteria [22] . Importantly, symptoms of orthostatic intolerance and number of syncopal events do not well discriminate between POTS and other syncope-related dysautonomic conditions, orthostatic hypotension and recurrent vasovagal syncope [22] . The onset of POTS may be precipitated by typical immunological stressors such as viral infection, frequently of the upper respiratory or gastrointestinal tract, vaccination, trauma, pregnancy, surgery or even a period of intensive psychosocial stress [17, 21, [23] [24] [25] [26] [27] [28] [29] . The antecedent history of suspected viral infection is reported by between 20% and 50% of all patients [23, 26] . However, a substantial number of POTS patients do not report any triggering event and experience rather slowly progressing or even stationary symptoms over a long period of time [21] . In patients with joint hypermobility syndrome, a variant of Ehlers-Danlos Syndrome, the onset of POTS may be insidious and the symptoms may develop over years beginning with teenage [27] .
Although the predominant and pathognomonic feature of POTS is chronic orthostatic intolerance, usually exacerbated by additional factors such as high ambient temperature, insufficient fluid intake, dehydration, physical strain, morning hours or fever, POTS patients typically present Table 2 ). The most common complaints in the initial presentation of POTS are dizziness, weakness, rapid heartbeat and palpitation on standing, headache, fatigue, abdominal pain and syncope [32] . Two of three patients report at least ten different symptoms [32] , which makes the diagnosis cumbersome for an untrained practitioner. In an UK study, patients waited approximately 4 years from presentation to obtain the correct diagnosis and a suspicion about psychiatric condition was common [33] .
In general, the symptoms related to POTS may be divided for the didactic purpose into two main groups, cardiovascular and noncardiovascular.
Cardiovascular symptoms
This group of symptoms is related to an inadequate and exaggerated heart rate increase on standing, global postural haemodynamic instability, either hypertensive or hypotensive tendency, cerebral hypoperfusion, venous pooling, and disorders of vascular tone regulation in specific areas such as head, coronary arteries, skin, extremities [20, 32, 34, 35] (Table 2) . Moreover, approximately 30-50% of all POTS patients faint [33, [35] [36] [37] .
Noncardiovascular symptoms
These symptoms are not directly related to the observed haemodynamic disorders [3, 5, 7, 20, 35] . The most important features are of a general nature and include non-specific physical deconditioning, reduced exercise capacity, fatigue and weakness ( Table 2 ). The most affected noncardiac areas are head and the nervous, respiratory, gastrointestinal and musculoskeletal systems. Some symptoms are a direct consequence of impaired autonomic regulation of basic homeostatic functions such as thermoregulation and peristalsis. The prevalence of different symptoms varies a lot, with some being more frequent, and other being less common [32, 38] .
The aetiology of POTS
There is a general consensus that POTS pathophysiology is complex as also is syndrome's clinical presentation [2, 5] . The heterogenous symptomatology, young age at onset and the presence of presumptive triggers in patient's history have led to the development of various hypotheses regarding syndrome's origin. Early clinical observations pointed to the fact that illness often started with an acute infection, typically viral, and that the onset was similar to Guillain-Barr e syndrome [7, 17] . This has directed attention to the possibility of immune involvement in POTS, although not unanimously accepted and rarely proven. There are, however, multiple facts supporting this idea. First, the predominance of women and temporal association with an antecedent viral infection, vaccination or trauma are similar to the typical features of autoimmune disease [39] . Secondly, indicators of immune system dysfunction and positive autoimmune tests are frequently seen among POTS patients. For instance, positive tests for antinuclear antibodies can be found in one of four POTS patients, whereas 20% report history of autoimmune disorders such as Hashimoto's thyroiditis, rheumatoid arthritis or Sj€ ogren syndrome [40] , more than expected in a general population [39] . In a series of 38 patients with POTS and gastrointestinal dysmotility, antiphospholipid antibodies were found in 76%, whereas novel Sjogren antibodies in 42% of all subjects [41] . However, the presence of these autoantibodies cannot satisfactorily explain the characteristic plethora of POTS symptoms, which rather suggests the overall immune system dysfunction and susceptibility to autoimmune disorders.
In recent years, search for the presence of a hypothetical immunological fingerprint in POTS has resulted in a discovery of diverse autoantibodies with a proposed causative role in the syndrome [25, 26, [40] [41] [42] [43] [44] [45] [46] [47] [48] . A specific focus was given cardiovascular G-protein-coupled membrane complexes, such as adrenergic, muscarinic and angiotensin II type-1 receptors The symptoms of POTS, especially [43, 45] (Fig. 1) . This attractive hypothesis awaits verification in larger and independent patient populations and wellselected control groups. An interested reader is recommended to consult some of recently published reviews on the subject [46, 48] . Other autoantibodies with a proposed aetiological role in POTS include antibodies against nicotinic acetylcholine-receptor in autonomic ganglia [26] and Sj€ ogren autoantibodies [41, 49] , detected in POTS through antibody screening programmes. A brief summary of autoimmune activity found in different POTS cohorts is presented in Table 3 .
The autoimmune hypothesis is not the only one, though. Other proposed pathomechanisms include disorders of autonomic cardiovascular regulation, both abnormally increased sympathetic activity and circulating catecholamine excess [7, 50] and peripheral sympathetic denervation leading to central hypovolaemia [51] [52] [53] . According to this hypothesis, increased central sympathetic outflow would explain inadequate sinus tachycardia, whereas venous pooling and reduced preload leading to compensatory heart rate elevation would be due to peripheral sympathetic denervation (Fig. 1 ). Both pathomechanisms, although apparently contradictory, if acting together, would result in characteristic postural tachycardia. It is unclear whether this cardiovascular autonomic dysfunction is of hereditary or rather acquired nature. Further, a subset of POTS patients demonstrate relative hypovolaemia and impaired renin-angiotensin-aldosterone regulation [54] . In these patients, POTS phenotype might be caused by neuroendocrine and renal dysfunction leading to chronic intravascular fluid deficiency. In opposite to the 'hypovolemic' subtype, another form of POTS, the 'hyperadrenergic' subtype was proposed [55] . In this form, which is characterized by high level of circulating norepinephrine during orthostasis, patients demonstrate tendency to orthostatic hypertension and often complain of extremity tremor, anxiety, migraine and angina-like chest pain [55] . In a subgroup of these patients, a rare mutation of norepinephrine-transporter gene was found, resulting in reduced synaptic norepinephrine reuptake and excessive sympathetic activation [56] . One might argue that the 'hypovolemic' subtype and peripheral sympathetic denervation are very close to each other, whereas the 'hyperadrenergic' subtype and abnormally increased sympathetic activity are two faces of the same condition. Apart from the most prevalent and classical 'hyperadrenergic' phenotype, symptoms of [34, 62] Active standing test The same diagnostic criteria as for head-up tilt test (Table 1) It may be used for initial screening and in clinics that lack access to fully equipped autonomic laboratory [5] . The chronotropic response may be blunted by patient using muscle pump [4, 5, 74] POTS -current views / A. Fedorowski abnormal sympathetic activation may be related in some patients to the abnormal mast cell activation. This specific subset of POTS is characterized by episodes of flushing, dyspnoea, headache, excessive diuresis and gastrointestinal symptoms such as diarrhoea, nausea and vomiting, accompanied by elevated urine methylhistamine [57] . Interestingly, a substantial proportion of POTS patients (20-50%) share diagnoses with chronic fatigue syndrome (CFS) and Ehlers-Danlos syndrome (EDS) [31, 33] . Among all CFS patients, around 10-15% meet diagnostic POTS criteria [58, 59] . These patients are typically younger and have shorter disease duration [59] . In EDS, characteristic POST symptoms can be found in up to 40% of patients and the onset is typically not precipitated by viral infection [60] .
The diagnosis of POTS
The diagnosis of POTS is difficult as it usually requires both doctor's vigilance combined with knowledge about the syndrome and an access to cardiovascular autonomic tests. A complicating factor is heterogeneity of symptoms that may mask the underlying POTS and divert clinician's attention towards other conditions with a similar presentation such as anxiety disorders, hyperthyroidism, pheochromocytoma, asthenia, orthostatic hypotension, hypocortisolaemia or other endocrinological disorders. An active standing test that can be easily performed may immediately give a diagnostic clue if supported by a history of characteristic chronic orthostatic intolerance, postural heart rhythm acceleration and varying panorama of accompanying complaints (Table 2 ). Further diagnostic process should be optimally delegated to a centre or specialist with a good experience of POTS. The golden standard for POTS diagnosis is head-up tilt test with a non-invasive beat-to-beat haemodynamic monitoring (Fig. 2) . A panel of additional tests may be performed to explore the haemodynamic profile of patient, differentiate between the 'hyperadrenergic' and 'neuropathic' form, and to grade the symptoms (Table 4 ; Fig. 3 ). In some dedicated autonomic centres, which are not widely available, a battery of autonomic tests can be offered to better categorize the affection and dysfunction of the entire autonomic nervous system [34, [61] [62] [63] , not only of its cardiovascular branch. Such tests may help the clinician and patient to better understand the individual spectrum of symptoms associated with POTS. They may also be applied to educate the patient about the non-pharmacological therapeutic measures to alleviate the noncardiovascular symptoms.
The management of POTS
The heterogeneity and wide spectrum of POTSrelated symptoms create a great challenge for clinicians and affected patients. Moreover, poorly explored pathophysiology of POTS makes it literally impossibly to treat the roots of disease and the management of POTS is usually focused on symptom alleviation [63, 64] . The long-term prognosis of POTS is not well explored. It is estimated that around 50% of all POTS patients spontaneously recover within 1-3 years [65] .
The first step in the appropriate management of POTS is the correct diagnosis. Patients should be comprehensively informed about the syndrome both verbally, using dedicated printed material, brochures, etc. and appropriate Internet links, if available. There are several non-profit patients' organizations in selected countries, the most active being www.dysautonomia international.org in the USA, and www.potsuk.org in the United Kingdom that support the research activities, inform about proceedings in the treatment of POTS and give practical advices to patients with POTS. After the diagnosis has been established, patient should be thoroughly educated about nonpharmacological measures alleviating the symptoms, long-term prognosis and available therapeutic options adequate to patient's status [5, 20, 34, 35, 63, 64] (Table 5 ). Here, the core impact relies on patient's education, including avoidance of orthostatic intolerance triggers and better understanding of POTS pathomechanisms. Exercise training may be very effective and has been shown to alleviate the symptoms of POTS-related deconditioning [66, 67] . If symptoms are pronounced, as evaluated by different symptom scores such as Orthostatic Hypotension Questionnaire (OHQ) [68] , and functional class 'pyramid' [69] focusing on complaints associated with orthostatic intolerance, or Karnofsky Performance Status [70] focusing on overall function limitation, the pharmacologic treatment should be considered. The most widely used drugs are presented in Table 5 . It should be kept in mind, however, that large randomized trials are not available [71] , there are no Class I recommendations to date [3] and the only Class IIA recommendations are exercise training against chronic symptoms and acute saline infusion in decompensated POTS [3] both with positive effects on plasma volume [72] . Among Class IIB recommendations are increased fluid and salt intake, midodrine, beta-blockers, fludrocortisone, pyridostigmine, clonidine and alpha-methyldopa [3] . Consequently, the physician and patient are often left alone with a decision which drug to test, in many situations applying an ex iuvantibus method, resulting in that polypharmacy is frequent. Typically, clinicians test various drugs directed at controlling heart rate, increasing peripheral vasoconstriction and increasing intravascular volume (Table 5 ). However, the overall effects of pharmacological therapy are modest and the most symptomatic patients remain severely affected by the disease even if combination of different drugs is applied [3, 71] .
Conclusions
Postural orthostatic tachycardia syndrome is a variant of cardiovascular autonomic disorder Fig. 3 The characteristic pattern of sinus tachycardia in patient with POTS during daily activities and after awakening (woman, 26 years old). Note that heart rate is distinctly lower (56 bpm) compared with awaken time (above 85 bpm). Arrows mark significant heart rate increase. Table 5 The most widely used empirical therapeutic options in postural orthostatic tachycardia syndrome
Therapy Comments
Non-pharmacological treatment Education of patient:
• Understanding of orthostatic intolerance and POTS pathophysiology
• Avoidance of immobilization, prolonged recumbency and physical deconditioning
• Gradual rising from supine and sitting position, especially in the morning, after meals, and after urination/defecation
• Small and frequent instead of large meals
• Avoidance of prolonged standing, high ambient temperature and high humidity
• Physical counter-manoeuvres (leg crossing, muscle tensing, squatting, etc.) during standing and prodromal symptoms [75] [76] [77] This point is crucial and should form the fundament of treatment [3, 4] .
It is rarely sufficient alone in pronounced symptoms. In-hospital acute 1-2 L physiological saline infusion (during consecutive 3-5 days)
In acute decompensated POTS, this method should be considered to alleviate the short-term symptoms. Class IIA recommendation [3, [103] [104] [105] BP, blood pressure.
POTS -current views / A. Fedorowski a substantial subset of patients recovering within few years after the initial presentation. The therapy of POTS relies on patients' education, non-pharmacological measures against orthostatic intolerance and drugs directed at controlling heart rate, increasing peripheral vasoconstriction and intravascular volume with limited efficacy in severe manifestations. Future efforts should focus on better understanding of POTS pathophysiology and designing randomized controlled trials for selection of more effective therapy.
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